Elicio Therapeutics, Inc. (ELTX) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Elicio Therapeutics is a clinical-stage biotechnology company developing next-generation immunotherapies targeting mutant KRAS (mKRAS)-positive cancers, primarily pancreatic ductal adenocarcinoma (PDAC). The Company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(20,040) | $(21,770) |
| Operating Expenses | $21,031 | $20,827 |
| Research & Development (R&D) | $13,568 | $14,784 |
| General & Administrative (G&A) | $7,463 | $6,043 |
| Cash Used in Operating Activities | $(19,810) | $(19,069) |
| Cash Provided by Financing Activities | $24,537 | $22,260 |
| Cash and Cash Equivalents (End of Period) | $23,480 | $22,088 |
| Long-Term Debt (Net) | $9,535 | $9,407 |
| Warrant Liabilities | $1,116 | $2,615 |
Note: The Company has no product revenue. Net loss per share (basic and diluted) was $(1.07) for the six months ended June 30, 2026.
Material Changes vs. Prior Period
- Net Loss Improvement: Net loss decreased by approximately 8% ($1.7 million) compared to the prior year period, primarily driven by a $1.5 million gain from the change in fair value of warrant liabilities.
- R&D Expenses: Decreased by $1.2 million (8%) due to lower clinical trial costs as the Phase 2 AMPLIFY-7P study transitioned from active dosing to the follow-up phase.
- G&A Expenses: Increased by $1.4 million (23%) due to increased headcount and professional fees.
- Financing Activity: The Company raised approximately $24.4 million net through At-The-Market (ATM) offerings during the six months ended June 30, 2026, compared to a mix of debt and equity financing in the prior year.
- Debt Position: The Company holds a $10.0 million Senior Secured Promissory Note (issued June 2025) with a carrying value of $9.5 million. A previous $20.0 million convertible note was fully converted to equity in March 2025.
Guidance, Outlook, and Risks
- Clinical Results (AMPLIFY-7P): In June 2026, the Company reported that the Phase 2 AMPLIFY-7P study did not meet its primary disease-free survival (DFS) endpoint in the intent-to-treat population. However, subgroup analyses showed early treatment benefits and a strong association between immune responses and clinical outcomes. The safety profile was favorable.
- Future Strategy: Management plans to refine the Phase 3 strategy for adjuvant PDAC based on subgroup data. Additionally, the Company intends to initiate a Phase 1 study in Q4 2026 evaluating ELI-002 7P in combination with a RAS inhibitor and/or anti-PD-1 inhibitor in metastatic PDAC.
- Liquidity and Going Concern: The filing explicitly states that the Company's losses, negative cash flows, and accumulated deficit raise substantial doubt about its ability to continue as a going concern. As of the filing date, cash on hand was projected to fund operations only into the first quarter of 2027.
- Subsequent Event: In July 2026, the Company completed a registered direct offering raising approximately $13.6 million net proceeds.
- Risks: Key risks include the failure of future clinical trials, inability to secure additional financing, competition from approved KRAS inhibitors, and potential safety issues with combination therapies.
Investor Verification Checklist
- Cash Runway: Verify the impact of the July 2026 financing ($13.6M) on the projected cash runway beyond Q1 2027.
- Phase 3 Design: Monitor upcoming disclosures regarding the specific design and patient stratification for the planned Phase 3 adjuvant PDAC trial following the AMPLIFY-7P results.
- Debt Covenants: Review the terms of the $10.0 million Senior Secured Promissory Note, specifically the interest rate (Prime + 5%, capped at 12.5%) and prepayment penalties.
- Dilution: Assess the dilution impact from the recent ATM offerings and the July 2026 registered direct offering on existing shareholders.
- Combination Trial Initiation: Confirm the start date of the planned Phase 1 combination study in metastatic PDAC and the availability of third-party combination agents.